GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Panion & Bf Biotech Inc (TPE:1760) » Definitions » EV-to-EBIT

Panion & Bf Biotech (TPE:1760) EV-to-EBIT : 38.26 (As of Sep. 26, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Panion & Bf Biotech EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Panion & Bf Biotech's Enterprise Value is NT$7,932 Mil. Panion & Bf Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was NT$207 Mil. Therefore, Panion & Bf Biotech's EV-to-EBIT for today is 38.26.

The historical rank and industry rank for Panion & Bf Biotech's EV-to-EBIT or its related term are showing as below:

TPE:1760' s EV-to-EBIT Range Over the Past 10 Years
Min: 17.04   Med: 40.36   Max: 654.43
Current: 38.27

During the past 13 years, the highest EV-to-EBIT of Panion & Bf Biotech was 654.43. The lowest was 17.04. And the median was 40.36.

TPE:1760's EV-to-EBIT is ranked worse than
82.95% of 440 companies
in the Biotechnology industry
Industry Median: 8.91 vs TPE:1760: 38.27

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Panion & Bf Biotech's Enterprise Value for the quarter that ended in Jun. 2024 was NT$8,952 Mil. Panion & Bf Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was NT$207 Mil. Panion & Bf Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 2.32%.


Panion & Bf Biotech EV-to-EBIT Historical Data

The historical data trend for Panion & Bf Biotech's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panion & Bf Biotech EV-to-EBIT Chart

Panion & Bf Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.31 78.77 33.45 45.06 54.40

Panion & Bf Biotech Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 89.40 219.67 54.40 47.11 43.18

Competitive Comparison of Panion & Bf Biotech's EV-to-EBIT

For the Biotechnology subindustry, Panion & Bf Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panion & Bf Biotech's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Panion & Bf Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Panion & Bf Biotech's EV-to-EBIT falls into.



Panion & Bf Biotech EV-to-EBIT Calculation

Panion & Bf Biotech's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=7931.952/207.319
=38.26

Panion & Bf Biotech's current Enterprise Value is NT$7,932 Mil.
Panion & Bf Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$207 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Panion & Bf Biotech  (TPE:1760) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Panion & Bf Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2024 ) =EBIT / Enterprise Value (Q: Jun. 2024 )
=207.319/8952.2465
=2.32 %

Panion & Bf Biotech's Enterprise Value for the quarter that ended in Jun. 2024 was NT$8,952 Mil.
Panion & Bf Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$207 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Panion & Bf Biotech EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Panion & Bf Biotech's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Panion & Bf Biotech Business Description

Traded in Other Exchanges
N/A
Address
No. 3, Park Street, 16th Floor, F Building, Nangang District, Taipei, TWN, 11503
Panion & Bf Biotech Inc operates as a biotech and pharmaceutical company. It is engaged in research and development of pharmaceuticals and new drugs. It focuses on pharmaceuticals, cosmeceuticals, nutraceuticals, and medical devices sectors. It has four core business groups such as disease treatment, disease prevention, disease diagnosis, and delayed aging. It has two geographic segments Taiwan segment and China, Hong Kong, and Macau segment. It generate majority of the revenue from Taiwan segment.

Panion & Bf Biotech Headlines

No Headlines